Clinical trials: Neoadjvant Therapy
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy samples.
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
- Trial name
- NCT05069857
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib (anti-VEGFR inhibitor)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma…
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
- Trial name
- NCT05125055
- Testing
- Toripalimab (anti-programmed death-1 inhibitor), Albumin paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Gastric Cancer Stage II, Gastric Cancer Stage III
Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer
Gastric cancer (GC) is one of the most common malignancies. According to the global cancer statistics 2018, there were 1,033,701 new cases of gastric cancer per year, ranked the fifth place in new tumors, and 782,685 deaths…
- Trial name
- NCT04119622
- Testing
- Toripalimab, oxaliplatin, capecitabine
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Aiping Zhou